Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Courses
  4. ESMO Virtual Advanced Course on Liquid Biopsy for Cancer Management June 2021

Session 3 - Quantitative Liquid-biopsy Biomarkers as Clinical Trials End Point

Role of cfDNA in Monitoring Response and Relapse: the Example of Liquid Biopsy Minimal Residual Disease as Clinical Trial Endpoint

Date

15 Jun 2021

Session

Session 3 - Quantitative Liquid-biopsy Biomarkers as Clinical Trials End Point

Topics

Targeted Therapy

Tumour Site

Presenters

V. Morris, US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.